Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease

Clinical and Experimental Nephrology

Volumn 17, Issue 4, 2013, Pages 488-497

  He, Jianhua ^a,b   Xu, Yong ^a   Koya, Daisuke ^b   Kanasaki, Keizo ^b  

^a THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Diabetes; EMT; EndMT; MicroRNAs; Transforming growth factor

Indexed keywords

ADAPTOR PROTEIN; ADVANCED GLYCATION END PRODUCT; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALVASCULIN; CD31 ANTIGEN; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; MICRORNA; MICRORNA 125B; MICRORNA 138; MICRORNA 148A; MICRORNA 200A; MICRORNA 200B; MICRORNA 21; MICRORNA 23; MICRORNA 23A; MICRORNA 23B; MICRORNA LET7B; MICRORNA LET7C; MICRORNA LET7D; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PROTEIN NCK2; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

CELL ADHESION; CELL INTERACTION; CELL POLARITY; CELL TRANSFORMATION; CHRONIC KIDNEY DISEASE; ENDOTHELIAL MESENCHYMAL TRANSITION; ENDOTHELIAL MYOFIBROBLAST TRANSITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

DISEASE PROGRESSION; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MYOFIBROBLASTS; RENAL INSUFFICIENCY, CHRONIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84883296447     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0781-0     Document Type: Review

References (87)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA, J Am Med Assoc. 2007;298:2038-47.
2. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
3. Cho MH. Renal fibrosis. Korean J Pediatr. 2010;53:735-40.
4. Boor P, Floege J. The renal (myo-)fibroblast: a heterogeneous group of cells. Nephrol Dial Transpl Off Publ Eur Dial Transpl Assoc Eur Renal Assoc. 2012;27:3027-36.
5. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 2010;225:631-7.
6. Barnes JL, Glass WF 2nd. Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts. Contrib Nephrol. 2011;169:73-93.
7. Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Investig. 2011;121:3981-90.
8. Piera-Velazquez S, Li Z, Jimenez SA. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am J Pathol. 2011;179:1074-80.
9. Markwald RR, Fizharris TP, Smith WN. Structural analysis of endocardial cytodifferentiation. Dev Biol. 1975; p. 160-80.
10. Mercado-Pimentel ME, Runyan RB. Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart. Cells Tissues Organs. 2007;185:146-56.
11. Kisanuki YY, Hammer RE, Miyazaki J, et al. Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol. 2001;230:230-42.
12. Rieder F, Kessler SP, West GA, et al. Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol. 2011;179:2660-73.
13. Zeisberg EM, Potenta SE, Sugimoto H, et al. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol JASN. 2008;19:2282-7.
14. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol. 2009;175:1380-8.
15. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7:684-96.
16. Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Semin Cancer Biol. 2012;22:379-84.
17. Medici D, Kalluri R. Endothelial-mesenchymal transition and its contribution to the emergence of stem cell phenotype. Seminars Cancer Biol. 2012.
18. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118:211-5.
19. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol. 2000;15:290-301.
20. Schmierer B, Hill CS. TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970-82.
21. Medici D, Shore EM, Lounev VY, et al. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16:1400-6.
22. Azhar M, Runyan RB, Gard C, et al. Ligand-specific function of transforming growth factor beta in epithelial-mesenchymal transition in heart development. Dev Dyn Off Publ Am Assoc Anat. 2009;238:431-42.
23. Boyer AS, Ayerinskas II, Vincent EB, et al. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol. 1999;208:530-45.
24. Medici D, Potenta S, Kalluri R. Transforming growth factor-beta2 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling. Biochem J. 2011;437:515-20.
25. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119:1420-8.
26. Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res. 2005;65:599-608.
27. Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370:341-7.
28. Li JH, Huang XR, Zhu HJ, et al. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int. 2003;63:2010-9.
29. Phanish MK, Wahab NA, Colville-Nash P, et al. The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J. 2006;393:601-7.
30. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol JASN. 2010;21:249-60.
31. Yang F, Chung AC, Huang XR, Lan HY. Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension. 2009;54:877-84.
32. Wang A, Ziyadeh FN, Lee EY, et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol. 2007;293:F1657-65.
33. Maleszewska M, Moonen JR, Huijkman N et al. IL-1beta and TGFbeta2 synergistically induce endothelial to mesenchymal transition in an NFkappaB-dependent manner. Immunobiology (in press).
34. Ma L, Lu MF, Schwartz RJ, Martin JF. Bmp2 is essential for cardiac cushion epithelial-mesenchymal transition and myocardial patterning. Development. 2005;132:5601-11.
35. McCulley DJ, Kang JO, Martin JF, Black BL. BMP4 is required in the anterior heart field and its derivatives for endocardial cushion remodeling, outflow tract septation, and semilunar valve development. Dev Dyn Off Publ Am Assoc Anat. 2008;237:3200-9.
36. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22:233-41.
37. Wang J, Sridurongrit S, Dudas M, et al. Atrioventricular cushion transformation is mediated by ALK2 in the developing mouse heart. Dev Biol. 2005;286:299-310.
38. Morrissey J, Hruska K, Guo G, et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol JASN. 2002;13(Suppl 1):S14-21.
39. Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol JASN. 2001;12:2392-9.
40. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem. 2004;279:23200-6.
41. Wang S, Hirschberg R. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol. 2003;284:F1006-13.
42. Zeisberg M, Hanai J, Sugimoto H. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Chronic Renal Injury. 2003; 9:964-8.
43. Satoh M, Kashihara N, Yamasaki Y, et al. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol JASN. 2001;12:317-25.
44. Tang R, Li Q, Lv L, et al. Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiovasc Diabetol. 2010;9:31.
45. Zhong J, Guo D, Chen CB, et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension. 2011;57:314-22.
46. Schulman IH, Zhou MS, Treuer AV, et al. Altered renal expression of angiotensin II receptors, renin receptor, and ACE-2 precede the development of renal fibrosis in aging rats. Am J Nephrol. 2010;32:249-61.
47. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45:163-9.
48. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Investig. 2007;117:524-9.
49. Kang KW. Angiotensin II-mediated Nrf2 down-regulation: a potential causing factor for renal fibrosis? Arch Pharmacal Res. 2011;34:695-7.
50. Phanish MK, Winn SK, Dockrell ME. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol. 2010;114:e83-92.
51. Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes. 2010;59:2612-24.
52. Li JH, Huang XR, Zhu HJ, et al. Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J Off Publ Fed Am Soc Exp Biol. 2004;18:176-8.
53. Ma J, Liu T, Dong X. Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades. Mol Vis. 2010;16:2669-79.
54. Fafeur V, Terman BI, Blum J, Bohlen P. Basic FGF treatment of endothelial cells down-regulates the 85-kDa TGF beta receptor subtype and decreases the growth inhibitory response to TGF-beta 1. Growth Factors. 1990;3:237-45.
55. Papetti M, Shujath J, Riley KN, Herman IM. FGF-2 antagonizes the TGF-beta1-mediated induction of pericyte alpha-smooth muscle actin expression: a role for myf-5 and Smad-mediated signaling pathways. Invest Ophthalmol Vis Sci. 2003;44:4994-5005.
56. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139-49.
57. Ramos C, Becerril C, Montano M, et al. FGF-1 reverts epithelial- mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell Mol Physiol. 2010;299:L222-31.
58. Chen PY, Qin L, Barnes C, et al. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Rep. 2012;2:1684-96.
59. Kumarswamy R, Volkmann I, Jazbutyte V, et al. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol. 2012;32:361-9.
60. Zhong X, Chung AC, Chen HY, et al. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol JASN. 2011;22:1668-81.
61. Lagendijk AK, Goumans MJ, Burkhard SB, Bakkers J. MicroRNA-23 restricts cardiac valve formation by inhibiting Has2 and extracellular hyaluronic acid production. Circ Res. 2011;109:649-57.
62. Ghosh AK, Nagpal V, Covington JW, et al. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): differential expression of microRNAs during EndMT. Cell Signal. 2012;24:1031-6.
63. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-4.
64. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589-97.
65. Saal S, Harvey SJ. MicroRNAs and the kidney: coming of age. Curr Opin Nephrol Hypertens. 2009;18:317-23.
66. Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol. 2007;211:585-9.
67. Cho JH, Gelinas R, Wang K, et al. Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes. BMC Med Genomics. 2011;4:8.
68. Song H, Wang Q, Wen J, et al. ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a. Int J Mol Sci. 2012;13:2063-77.
69. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;182:220-9.
70. Yang S, Banerjee S, de Freitas A, et al. Participation of miR-200 in pulmonary fibrosis. Am J Pathol. 2012;180:484-93.
71. Xiong M, Jiang L, Zhou Y, et al. The miR-200 family regulates TGF-beta1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J Physiol Renal Physiol. 2012;302:F369-79.
72. Oba S, Kumano S, Suzuki E, et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS ONE. 2010;5:e13614.
73. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008;283:14910-4.
74. Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593-601.
75. Yamasaki T, Seki N, Yamada Y, et al. Tumor suppressive microRNA138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol. 2012;41:805-17.
76. Papadimitriou E, Vasilaki E, Vorvis C, et al. Differential regulation of the two RhoA-specific GEF isoforms Net1/Net1A by TGF-beta and miR-24: role in epithelial-to-mesenchymal transition. Oncogene. 2012;31:2862-75.
77. Du R, Sun W, Xia L, et al. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS ONE. 2012;7:e30771.
78. Kriegel AJ, Fang Y, Liu Y, et al. MicroRNA-target pairs in human renal epithelial cells treated with transforming growth factor beta 1: a novel role of miR-382. Nucleic Acids Res. 2010;38:8338-47.
79. Wang B, Herman-Edelstein M, Koh P, et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes. 2010;59:1794-802.
80. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3- driven renal fibrosis. J Am Soc Nephrol JASN. 2010;21:1317-25.
81. Kato M, Zhang J, Wang M, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci USA. 2007;104:3432-7.
82. Kanasaki M, Nagai T, Kitada M, et al. Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors. Fibrogenesis & tissue repair. 2011;4:25.
83. Mathew A, Cunard R, Sharma K. Antifibrotic treatment and other new strategies for improving renal outcomes. Contrib Nephrol. 2011;170:217-27.
84. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97:512-23.
85. Zeisberg EM, Potenta S, Xie L, et al. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123-8.
86. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
87. Shang H, Nitsche E, Jing X, et al. Inhibition of TGF-beta signaling by miR-23b [abstract]. J Am Soc Nephrol. 2008;19:143A.